Abrupt-onset diabetes mellitus secondary to pembrolizumab
Endocrinol Diabetes Nutr (Engl Ed)
.
2023 Jan;70(1):71-73.
doi: 10.1016/j.endien.2022.06.013.
Epub 2023 Jan 23.
Authors
Adrián Pastor Alcaraz
1
,
Luis Marín Martínez
2
,
Georgios Kyriakos
2
,
María C Álvarez Martín
2
,
Enrique Hernández Alonso
2
Affiliations
1
Servicio de Endocrinología y Nutrición, Hospital General Universitario Santa Lucía, Cartagena, Spain. Electronic address: adri_v_a@hotmail.com.
2
Servicio de Endocrinología y Nutrición, Hospital General Universitario Santa Lucía, Cartagena, Spain.
PMID:
36697277
DOI:
10.1016/j.endien.2022.06.013
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Diabetes Mellitus, Type 1*
Humans
Substances
pembrolizumab
Antibodies, Monoclonal, Humanized